Sign In
Buy AMRX
$18.09
+0.170 (+0.95%)
At Close: Jul 27, 2026
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call Transcript
11:32am, Friday, 02'nd May 2025
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q1 2025 Earnings Call May 2, 2025 8:30 AM ET Company Participants Tony DiMeo - Head, Investor Relations Chirag Patel - Co-Founder and Co-Chief Executive Off
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:35am, Friday, 02'nd May 2025
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street e
Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates
08:10am, Friday, 02'nd May 2025
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.14 per share a year ago.
Amneal Reports First Quarter 2025 Financial Results
06:00am, Friday, 02'nd May 2025
BRIDGEWATER, N.J.--(BUSINESS WIRE)--AMNEAL REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS.
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
11:06am, Friday, 25'th Apr 2025
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month
08:00am, Friday, 11'th Apr 2025
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month.
BRIDGEWATER, N.J.--(BUSINESS WIRE)--New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® Extended-Release Capsules in Parkinson's Disease.
Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma
08:00am, Tuesday, 01'st Apr 2025
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and Shilpa Medicare Limited (“Shilpa”) toda
Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued
03:14pm, Wednesday, 19'th Mar 2025
Amneal Pharmaceuticals, Inc. seems fundamentally undervalued, with a market cap significantly lower than peers despite similar revenue levels, suggesting potential for substantial stock price apprecia
Amneal to Participate at Upcoming Investor Conference
04:05pm, Monday, 10'th Mar 2025
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Participate at Upcoming Investor Conference.
Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
04:05pm, Monday, 03'rd Mar 2025
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA.
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2024 Earnings Call Transcript
02:20pm, Friday, 28'th Feb 2025
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President and Co-C
Here's What Key Metrics Tell Us About Amneal (AMRX) Q4 Earnings
10:30am, Friday, 28'th Feb 2025
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare
Amneal Pharmaceuticals (AMRX) Q4 Earnings Lag Estimates
08:15am, Friday, 28'th Feb 2025
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.14 per share a year ago.
Amneal Reports Fourth Quarter and Full Year 2024 Financial Results
06:00am, Friday, 28'th Feb 2025
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Reports Fourth Quarter and Full Year 2024 Financial Results.
